Total Payments
$1,550
2024 Payments
$813.57
Companies
13
Transactions
74
Medicare Patients
830
Medicare Billing
$117,178
Payment Breakdown by Category
Food & Beverage$1,406 (90.7%)
Education$143.99 (9.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,406 | 72 | 90.7% |
| Education | $143.99 | 2 | 9.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $340.31 | 19 | $0 (2024) |
| Insmed, Inc. | $284.92 | 4 | $0 (2024) |
| ABBVIE INC. | $283.50 | 17 | $0 (2024) |
| Merck Sharp & Dohme LLC | $206.16 | 11 | $0 (2024) |
| Astellas Pharma US Inc | $107.25 | 4 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $92.78 | 6 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $65.67 | 4 | $0 (2023) |
| AIMMUNE THERAPEUTICS, INC. | $46.22 | 3 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $36.40 | 2 | $0 (2024) |
| Gilead Sciences, Inc. | $32.00 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $813.57 | 37 | ABBVIE INC. ($181.63) |
| 2023 | $671.88 | 34 | Merck Sharp & Dohme LLC ($166.98) |
| 2022 | $64.05 | 3 | Gilead Sciences, Inc. ($32.00) |
All Payment Transactions
74 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $17.57 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 12/03/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $18.35 | General |
| Category: VIROLOGY | ||||||
| 11/25/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 11/20/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ, DALVANCE | Food and Beverage | In-kind items and services | $12.19 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/19/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $28.30 | General |
| Category: HIV | ||||||
| 11/15/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: ANTIBIOTIC | ||||||
| 11/12/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: VACCINES | ||||||
| 11/06/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: Dermatology | ||||||
| 10/23/2024 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $28.26 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/22/2024 | Echosens North America, Inc. | FibroScan (Device) | Food and Beverage | Cash or cash equivalent | $19.69 | General |
| Category: Elastography | ||||||
| 10/14/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $44.99 | General |
| 10/10/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $25.19 | General |
| Category: Infectious Diseases | ||||||
| 10/01/2024 | Merck Sharp & Dohme LLC | CAPVAXIVE (Biological) | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: VACCINE | ||||||
| 09/11/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO, AVYCAZ | Food and Beverage | In-kind items and services | $11.13 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/06/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $14.32 | General |
| 09/05/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: HIV | ||||||
| 07/17/2024 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/17/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $13.23 | General |
| Category: Dermatology | ||||||
| 06/18/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $21.62 | General |
| Category: HIV | ||||||
| 06/12/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $22.07 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/05/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO, AVYCAZ | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/31/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: ANTIBIOTIC | ||||||
| 05/22/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $12.56 | General |
| Category: HIV | ||||||
| 05/09/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ, DALVANCE | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/24/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $144.95 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 147 | 290 | $92,993 | $30,298 |
| 2022 | 5 | 160 | 241 | $45,045 | $14,319 |
| 2021 | 7 | 213 | 281 | $148,457 | $48,828 |
| 2020 | 6 | 310 | 523 | $186,511 | $23,733 |
Total Patients
830
Total Services
1,335
Medicare Billing
$117,178
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 64 | 162 | $56,700 | $18,348 | 32.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 56 | 101 | $25,250 | $8,105 | 32.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $11,043 | $3,845 | 34.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 44 | 67 | $16,189 | $5,306 | 32.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 45 | 69 | $11,097 | $3,744 | 33.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 23 | 34 | $7,786 | $2,285 | 29.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 29 | 50 | $7,936 | $2,280 | 28.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 19 | 21 | $2,037 | $704.47 | 34.6% |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | Office | 2021 | 85 | 85 | $84,150 | $34,442 | 40.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 36 | 74 | $18,994 | $4,824 | 25.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 25 | 41 | $9,553 | $3,518 | 36.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 20 | 21 | $9,387 | $2,727 | 29.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 19 | 32 | $14,632 | $1,514 | 10.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 16 | $2,576 | $965.44 | 37.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 12 | 12 | $9,165 | $838.20 | 9.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 119 | 263 | $98,442 | $12,385 | 12.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 79 | 79 | $43,333 | $5,499 | 12.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 53 | 121 | $23,484 | $3,083 | 13.1% |
| 99217 | Hospital observation care on day of discharge | Facility | 2020 | 26 | 26 | $8,183 | $937.68 | 11.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 13 | 14 | $8,962 | $925.99 | 10.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 20 | 20 | $4,106 | $901.84 | 22.0% |
About Sara Rogers, DNP
Sara Rogers, DNP is a Acute Care healthcare provider based in Albuquerque, New Mexico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/25/2012. The National Provider Identifier (NPI) number assigned to this provider is 1801167614.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Sara Rogers, DNP has received a total of $1,550 in payments from pharmaceutical and medical device companies, with $813.57 received in 2024. These payments were reported across 74 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($1,406).
As a Medicare-enrolled provider, Rogers has provided services to 830 Medicare beneficiaries, totaling 1,335 services with total Medicare billing of $117,178. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Acute Care
- Other Specialties Adult Health, Adult Health
- Location Albuquerque, NM
- Active Since 01/25/2012
- Last Updated 01/05/2023
- Taxonomy Code 363LA2100X
- Entity Type Individual
- NPI Number 1801167614
Products in Payments
- Arikayce (Drug) $284.92
- DOVATO (Drug) $231.21
- PIFELTRO (Drug) $166.98
- DALVANCE (Drug) $142.79
- TEFLARO (Drug) $72.10
- REBYOTA (Biological) $65.67
- COSENTYX (Drug) $65.28
- CABENUVA (Biological) $65.13
- Cresemba (Drug) $62.26
- ZENPEP (Drug) $46.22
- APRETUDE (Biological) $43.97
- MAVYRET (Drug) $40.21
- NUZYRA (Drug) $36.40
- Epclusa (Drug) $32.00
- AVYCAZ (Drug) $28.40
- DIFICID (Drug) $22.07
- FibroScan (Device) $19.69
- PREVNAR 20 (Biological) $19.61
- CAPVAXIVE (Biological) $17.11
- SHINGRIX (Biological) $14.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Acute Care Doctors in Albuquerque
Catherine Mahoney, Cnp, CNP
Acute Care — Payments: $6,655
Acute Care $6,655
Christina Parks, Cnp, CNP
Acute Care — Payments: $6,544
Acute Care $6,544
Samantha Matteucci, Acnpc-Ag, ACNPC-AG
Acute Care — Payments: $6,193
Acute Care $6,193
Taryn Denezpi, Acnpc-Ag, ACNPC-AG
Acute Care — Payments: $5,127
Acute Care $5,127
Mrs. Isabel Torres, Cnp, CNP
Acute Care — Payments: $4,602
Acute Care $4,602
Ms. Pamela Parker, Arnp, ARNP
Acute Care — Payments: $3,537
Acute Care $3,537